Pulse Biosciences develops bioelectric medicine technology based on its proprietary nPulse platform, which uses nanosecond pulsed field ablation energy to deliver nanosecond electrical pulses for non-thermal cell clearing. Company news commonly centers on the nPulse Cardiac Catheter System for atrial fibrillation, clinical study disclosures, feasibility data, and presentations at electrophysiology and healthcare conferences.
Recurring updates also cover the company's work in selected applications such as surgical soft tissue ablation, investor presentations and analyst events, executive leadership changes, operating and financial results, governance matters, and capital-structure disclosures related to its common stock and financing programs.
Pulse Biosciences (Nasdaq: PLSE) reported Q3 2025 business updates and financial results for the quarter ended September 30, 2025. Key clinical milestones include FDA IDE approval and initial enrollment in the nPulse Cardiac Surgery System surgical AF study (NANOCLAMP AF), PRECISE-BTN study 40% enrolled for benign thyroid nodules, and submission/planned IDE start for the endocardial nPulse 360° catheter in Q1 2026. The company has treated over 200 patients across programs and generated $86 thousand revenue from limited market release.
Q3 GAAP costs and expenses were $20.5M (GAAP net loss $19.4M); non-GAAP loss was $13.5M. Cash and equivalents were $95.2M at September 30, 2025.
Pulse Biosciences (Nasdaq: PLSE) announced first U.S. patient enrollment in the NANOCLAMP AF Study on October 24, 2025, using the nPulse Cardiac Surgical System after receiving FDA IDE approval.
The single-arm, prospective multicenter study will evaluate safety and effectiveness of the nsPFA-driven nPulse Cardiac Clamp for atrial fibrillation during concomitant surgical procedures, with multiple U.S. and two international sites planned. The device holds FDA Breakthrough Device designation (July 2024) and is in the FDA TPLC Advisory Program.
Pulse Biosciences (Nasdaq: PLSE) will report third quarter 2025 business updates and financial results after market close on Wednesday, November 5, 2025.
Company management will host a conference call on November 5, 2025 at 1:30 PM PT / 4:30 PM ET. U.S. dial-in is 1-800-715-9871; international dial-in is 1-646-307-1963; use Conference ID 7706791. A live and recorded webcast will be available on the Pulse Biosciences investors website at http://investors.pulsebiosciences.com/.
Pulse Biosciences (Nasdaq: PLSE) announced that its Compensation Committee granted inducement equity awards to three new employees on October 14, 2025 under the company’s 2017 Inducement Equity Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
The awards total up to 8,550 options to purchase common stock at an exercise price of $17.26 per share (equal to the October 14, 2025 closing price). Options vest over four years with 1/4 vesting annually and are subject to the plan and individual award agreements.
Pulse Biosciences (Nasdaq: PLSE) reported late-breaking first-in-human feasibility results for the nPulse™ Cardiac Surgical System presented at EACTS on October 10, 2025. The study has treated 44 patients, with electroanatomical mapping at ~3 months in 24 patients. Key outcomes in the initial cohort include 100% posterior box isolation (high-dose cohort), 94% pulmonary vein isolation per vein (63/67) at ~3 months, an average total ablation time of 50 seconds with ~13 applications, and no reports of esophageal or phrenic nerve injury or ablation-related severe/major adverse events. The company plans to initiate an IDE study later in 2025 to further validate the system for AF surgical ablation.
Pulse Biosciences (Nasdaq: PLSE) announced that early clinical data on its nPulse™ Cardiac Surgical System using nanosecond PFA (nsPFA) for atrial fibrillation will be presented at the 39th EACTS Annual Meeting in Copenhagen, October 8–11, 2025.
The company noted the FDA approval of an IDE study for the nPulse system and said clinicians will present safety and efficacy findings. Scheduled events include a presentation by Bart van Putte, MD on October 8 (Acquired Cardiac Techno-College, presentation at 10:40 AM, Hall A1) and a moderated e-poster on October 10 (First‑in‑Human nsPFA study, 12:30–1:00 PM, Moderated e‑Poster Station 2).
Pulse Biosciences (Nasdaq: PLSE), a company specializing in nPulse™ and Nanosecond Pulsed Field Ablation™ technology, has granted equity inducement awards to four new employees. The Compensation Committee approved stock options to purchase a total of 20,850 shares of common stock at an exercise price of $15.74 per share, matching the closing price on September 15, 2025.
The awards, granted outside the Company's 2017 Equity Incentive Plan but under the 2017 Inducement Equity Incentive Plan, will vest over four years with 25% vesting annually, contingent on continued employment.
[]Pulse Biosciences (Nasdaq: PLSE) announced the presentation of clinical data on benign thyroid nodule ablation using their nPulse™ Vybrance™ technology at the American Thyroid Association Annual Meeting in Scottsdale, AZ, from September 10-14th, 2025.
The company will showcase its novel Nanosecond Pulsed Field Ablation™ (nsPFA™) technology through multiple presentations, including a late-breaking oral abstract session by Dr. Ralph Tufano and a sponsored event featuring clinical experiences from leading physicians. The company has recently initiated patient treatments in their multicenter IRB study and aims to expand clinical evidence supporting their technology.
Pulse Biosciences (NASDAQ: PLSE) has received FDA Investigational Device Exemption (IDE) approval to begin its NANOCLAMP AF study for treating atrial fibrillation using their novel Nanosecond Pulsed Field Ablation (nsPFA) Cardiac Surgery System. The study will enroll up to 136 patients across 20 sites, including two international locations.
The company's nsPFA technology represents a breakthrough in cardiac ablation, offering a nonthermal approach that may provide significant advantages over traditional thermal methods like radiofrequency ablation. Early clinical data from the ongoing EU feasibility study, which has treated over 40 patients, shows promising results with rapid ablation times as fast as 2.5 seconds.
The nsPFA Cardiac Surgical System previously received FDA Breakthrough Device Designation in July 2024 and is part of the FDA's Total Product Life Cycle Advisory Program.
Pulse Biosciences (Nasdaq: PLSE), a nanosecond Pulsed Field Ablation technology company, has granted equity inducement awards to two new employees. The Compensation Committee approved stock options to purchase 3,950 shares of common stock at an exercise price of $16.16 per share, equal to the closing price on August 15, 2025.
The options will vest over four years with 25% vesting annually, contingent on continued employment. These grants were made outside the Company's 2017 Equity Incentive Plan but under the 2017 Inducement Equity Incentive Plan, in compliance with Nasdaq Listing Rule 5635(c)(4).